ng28ÄϹ¬ºÍ²³½¡Ðû²¼£¬ÖйúÏã¸ÛÌرðÐÐÕþÇøÕþ¸®ÎÀÉúÊðÒÑÅú×¼ÈËÔ´»¯¿¹¿ÉÈÜÐÔ¾Û¼¯µí·ÛÑùÂÑ°×-¦Â£¨A¦Â£©µ¥¿Ë¡¿¹ÌåÂØ¿¨Ä¹£¨Ïã¸ÛÉÌÆ·Ãû£ºÀÖÒâ±£?£©ÓÃÓÚÖÎÁÆ°¢¶û´Äº£Ä¬²¡¡£ÂØ¿¨Ä¹µÄÖÎÁÆÊÊÓÃÓÚÇá¶ÈÈÏÖªÕÏ°­»òÇá¶È³Õ´ô½×¶ÎµÄ»¼Õߣ¬¼´£ºÁÙ´²ÊÔÑéÖпªÊ¼ÖÎÁƵÄÈËȺ¡£

 

ÂØ¿¨Ä¹¿ÉÒÔÑ¡ÔñÐÔ½áºÏ¿ÉÈÜÐÔA¦Â¾Û¼¯Ì壨ԭÏËά*£©£¬ÒÔ¼°ADÖÐA¦Â°ß¿éµÄÖ÷ÒªÉí·Ö¡ª¡ª²»ÈÜÐÔA¦Â¾Û¼¯Ì壨ÏËά£©£¬´Ó¶ø¼õÉÙ´óÄÔÖеÄA¦ÂÔ­ÏËάºÍA¦Â°ß¿é¡£ÂØ¿¨Ä¹ÊÇÊ׸ö±»ÍêÈ«Åú×¼µÄͨ¹ý¸Ã»úÖƽµµÍ¼²²¡½øÕ¹ËٶȲ¢¼õ»ºÈÏÖªºÍ´óÄÔ¹¦Ð§Ë¥Í˵ÄÖÎÁÆÒªÁì¡£ÖйúÏã¸ÛÊǼÌÃÀ¹ú¡¢ÈÕ±¾¡¢Öйú¡¢º«¹úÖ®ºó£¬µÚÎå¸öÅú×¼¸ÃÒ©Æ·µÄ¹ú¼ÒºÍµØÇø¡£

 

ÂØ¿¨Ä¹ÔÚÖйúÏã¸Û»ñÅú£¬ÊÇ»ùÓÚÈ«Çò´óÐÍIIIÆÚÑо¿Clarity AD¡£ÔÚClarity ADÑо¿ÖУ¬ÂØ¿¨Ä¹µÖ´ïÁËÖ÷ÒªÖÕµãºÍËùÓÐÒªº¦´ÎÒªÖյ㣬ÇÒ½á¹û¾ßÓÐͳ¼ÆѧÒâÒå^1£¬2¡£ÔÚÖйúÏã¸Û£¬70Ëê¼°ÒÔÉÏÈËȺÖÐÓÐ 9.3% »¼ÓгմôÖ¢£¬85Ëê¼°ÒÔÉÏÈËȺÖеÄÕâÒ»±ÈÀýÔöÖÁ 32%£¬ÆäÖÐ 73.5% ¾Ý±¨¸æ»¼Óа¢¶û´Äº£Ä¬²¡^3£¬4¡£

 

ÂØ¿¨Ä¹µÄÈ«Çò¿ª·¢ºÍ×¢²áÉêÇëÓÉng28ÄϹ¬Ö÷µ¼£¬¶ø²úÆ·ÔòÓÉng28ÄϹ¬ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍƹã¡£ÆäÖУ¬ng28ÄϹ¬ÓµÓÐ×îÖÕ¾ö²ßȨ¡£ng28ÄϹ¬½«ÂôÁ¦¸Ã²úÆ·ÔÚÖйúÏã¸ÛµÄÉÌÒµÍƹã¡£

 

*Ô­ÏËά±»ÈÏÊǵ¼ÖÂAD»¼ÕßµÄÄÔËðÉ˵ÄÔªÐ×£¬ÆäËùº¬¶¾ÐÔÊÇA¦ÂÖÐ×î´óµÄ£¬ÔÚÓëÕâÖÖ½øÐÐÐÔË¥ÈõµÄ¼²²¡Ïà¹ØµÄÈÏ֪˥ÍËÖÐÆðÖ÷Òª×÷ÓÃ⁵¡£Ô­ÏËά¶Ô´óÄÔÉñ¾­ÔªÔì³ÉËðÉË£¬½ø¶øͨ¹ý¶àÖÖ»úÖƶÔÈÏÖª¹¦Ð§±¬·¢¸ºÃæÓ°Ï죬²»µ«Ôö¼ÓÁ˲»ÈÜÐԦ°߿éµÄÐγÉ£¬²¢ÇÒÔö¼ÓÁ˶ÔÄÔϸ°ûĤºÍÉñ¾­Ï¸°ûÖ®¼ä»òÉñ¾­Ï¸°ûÓëÆäËûϸ°ûÖ®¼äͨ±¨ÐźŵÄÁ¬½ÓµÄÖ±½ÓËðÉË¡£¼õÉÙÔ­ÏËά¿É¼õÉÙ¶Ô´óÄÔÉñ¾­ÔªµÄËðÉ˺ÍÈÏÖª¹¦Ð§ÕÏ°­À´×èÖ¹°¢¶û´Äº£Ä¬²¡µÄ½øÕ¹⁶¡£

 

References

1. Eisai presents full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer’s disease at Clinical Trials on Alzheimer’s Disease (CTAD) conference. Available at: https://www.eisai.co.jp/news/2022/news202285.html
2. van Dyck, H., et al. Lecanemab in Early Alzheimer¡¯s Disease. New England Journal of Medicine. 2023;388:9-21. https://www.nejm.org/doi/full/10.1056/NEJMoa2212948.
3. Department of Health – Press Release ¡°Dementia Care Seminar cum Kick-off Ceremony for Dementia Care Campaign. Available at: https://www.dh.gov.hk/english/press/2006/061013.html
4. Ruby Yu , et al. Trends in Prevalence and Mortality of Dementia inElderly Hong Kong Population: Projections, Disease Burden, andImplications for Long-Term Care. Int J Alzheimer¡¯s Dis. 2012(7593):406852. doi: 10.1155/2012/406852
5. Amin L, Harris DA. A¦Â receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z
6. Ono K, Tsuji M. Protofibrils of Amyloid-¦Â are Important Targets of a Disease-Modifying Approach for Alzheimer’s Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.